文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

印度放射治疗利用情况的流行病学分析及其对癌症护理的影响——来自国家癌症登记计划的见解

Epidemiological analysis of radiation therapy utilization and its implications for cancer care in India-insights from National Cancer Registry Programme.

作者信息

Sankarapillai Jayasankar, Ramamoorthy Thilagavathi, Sarveswaran Gokul, Venugopal Gopika, Mathur Prashant

机构信息

Indian Council of Medical Research - National Centre for Disease Informatics and Research, Nirmal Bhawan-ICMR Complex (II Floor), Adjacent to Trumpet Flyover of BIAL, Poojanahalli Road, Off NH-7,Kannamangala Post, Karnataka, Bengaluru, 562 110, India.

出版信息

BMC Cancer. 2025 Jul 1;25(1):1062. doi: 10.1186/s12885-025-14440-1.


DOI:10.1186/s12885-025-14440-1
PMID:40598031
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12210425/
Abstract

AIM: Radiotherapy is a cornerstone of cancer treatment in India, yet its expansion is hindered by high investment costs. Effective planning and target estimation based on cancer burden are crucial to meet the radiotherapy demands of patients with cancer. METHODS: Data from Australian Collaboration for Cancer Outcomes Research and Evaluation (CCORE) were used. Epidemiological data on stage, subsite and histology from National cancer registry programme were used to assess the optimal utilization proportion for India. A sensitivity analysis was carried out. Similarly optimal radiotherapy fraction has also being calculated. These measures have been used to estimate the existing radiotherapy utilization gap by comparing with the current radiotherapy utilization from cancer registry as well as estimate the optimal radiotherapy machines required for the country. RESULTS: Optimal radiotherapy utilization rate in India is 58.4% (95% CI: 57.6-58.9), whereas the actual utilization rate is 28.5% (95% CI: 28.0-31.5). The estimated number of radiotherapy machines required to meet demand ranges from 1,585 to 2,545. CONCLUSION: The study highlights a substantial shortfall in radiotherapy utilisation across all cancer types and underscores the need for interventions to meet the gap in machines required for an equitable cancer care. Efforts to reduce the cancer burden in the country shall influence the radiotherapy requirement through early stage diagnosis and treatment. Advancement in other modalities of treatment shall need to watch closely.

摘要

目的:放射治疗是印度癌症治疗的基石,但其扩展受到高昂投资成本的阻碍。基于癌症负担进行有效的规划和目标估计对于满足癌症患者的放射治疗需求至关重要。 方法:使用了来自澳大利亚癌症结局研究与评估合作组织(CCORE)的数据。利用国家癌症登记计划中关于分期、亚部位和组织学的流行病学数据来评估印度的最佳利用比例。进行了敏感性分析。同样也计算了最佳放疗分割次数。通过与癌症登记处当前的放疗利用率进行比较,这些措施被用于估计现有的放疗利用差距,以及估计该国所需的最佳放疗设备数量。 结果:印度的最佳放疗利用率为58.4%(95%可信区间:57.6 - 58.9),而实际利用率为28.5%(95%可信区间:28.0 - 31.5)。满足需求所需的放疗设备估计数量在1585至2545台之间。 结论:该研究凸显了所有癌症类型放疗利用方面的巨大缺口,并强调需要采取干预措施来填补公平癌症治疗所需设备的差距。该国减轻癌症负担的努力将通过早期诊断和治疗影响放疗需求。需要密切关注其他治疗方式的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589c/12210425/5774d1bc90a9/12885_2025_14440_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589c/12210425/2e7ed0f79389/12885_2025_14440_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589c/12210425/5774d1bc90a9/12885_2025_14440_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589c/12210425/2e7ed0f79389/12885_2025_14440_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589c/12210425/5774d1bc90a9/12885_2025_14440_Fig2_HTML.jpg

相似文献

[1]
Epidemiological analysis of radiation therapy utilization and its implications for cancer care in India-insights from National Cancer Registry Programme.

BMC Cancer. 2025-7-1

[2]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Health Technol Assess. 2001

[3]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

[4]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Health Technol Assess. 2001

[5]
Management of urinary stones by experts in stone disease (ESD 2025).

Arch Ital Urol Androl. 2025-6-30

[6]
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.

JBI Database System Rev Implement Rep. 2016-4

[7]
Interventions for promoting habitual exercise in people living with and beyond cancer.

Cochrane Database Syst Rev. 2018-9-19

[8]
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.

Health Technol Assess. 2024-10

[9]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[10]
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Health Technol Assess. 2007-11

本文引用的文献

[1]
Global linear accelerator requirements and personalised country recommendations: a cross-sectional, population-based study.

Lancet Oncol. 2025-2

[2]
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study.

Lancet Glob Health. 2024-12

[3]
Current and projected gaps in the availability of radiotherapy in the Asia-Pacific region: a country income-group analysis.

Lancet Oncol. 2024-2

[4]
Utilisation of radiotherapy in lung cancer: A scoping narrative literature review with a focus on the introduction of evidence-based therapeutic approaches in Europe.

Clin Transl Radiat Oncol. 2023-12-18

[5]
Measuring Global Inequity in Radiation Therapy: Resource Deficits in Low- and Middle-Income Countries Without Radiation Therapy Facilities.

Adv Radiat Oncol. 2023-3-1

[6]
Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India.

Indian J Med Res. 2022

[7]
Global Radiotherapy: Current Status and Future Directions-White Paper.

JCO Glob Oncol. 2021-6

[8]
Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.

JCO Glob Oncol. 2020-7

[9]
Radiotherapy for Non-Hodgkin Lymphomas.

Cancer J. 2020

[10]
Radiotherapy in India: History, current scenario and proposed solutions.

Indian J Cancer. 2019

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索